Dr Raquel Maria Bravo-clouzet, MD, MPH | |
5301 E Grant Rd, Tucson, AZ 85712-2805 | |
(520) 324-2594 | |
Not Available |
Full Name | Dr Raquel Maria Bravo-clouzet |
---|---|
Gender | Female |
Speciality | Student In An Organized Health Care Education/training Program |
Location | 5301 E Grant Rd, Tucson, Arizona |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1356909881 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208M00000X | Hospitalist | R77502 (Arizona) | Secondary |
390200000X | Student In An Organized Health Care Education/training Program | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Raquel Maria Bravo-clouzet, MD, MPH 5301 E Grant Rd, Tucson, AZ 85712-2805 Ph: () - | Dr Raquel Maria Bravo-clouzet, MD, MPH 5301 E Grant Rd, Tucson, AZ 85712-2805 Ph: (520) 324-2594 |
News Archive
The American Academy of Sleep Medicine (AASM), an organisation that supports and promotes better sleep health, has released guidelines on the number of hours of sleep that children and teenagers need to minimise sleep related health problems.
Amadeus Consulting, a custom software development company, recently developed iBirth for Android a mobile application for Lula B, LLC. Created by two mothers in Boulder, Colorado, Lula B wanted an app to help women through the childbirth process to ensure they have the information available for a safe, healthy, and empowering pregnancy.
Female doctors who suffer domestic abuse can feel unable to get help due to perceptions that it "should not happen to a doctor" and a judgemental culture in medical settings, a new study suggests.
Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced four-year follow-up results from a Phase 3 randomized, open-label, dose-optimization study of SPRYCEL® (dasatinib) in chronic-phase chronic myeloid leukemia (CML-CP) patients resistant or intolerant to Gleevec®* (imatinib mesylate). At four years, for all patients administered SPRYCEL 100 mg once daily, overall survival was 82% (95% CI: 76%-88%) and progression-free survival was 66% (95% CI: 57%-74%).
› Verified 6 days ago